AFP and hepatocellular carcinoma: Most guidelines insist surveillance for hepatocellular carcinoma (HCC) of high-risk patients with chronic liver diseases by ultrasonography (USG) every 6 months [with or without alpha-fetoprotein (AFP)] [1,2].